Cancer drug extension study offers hope for continued treatment

NCT ID NCT00959647

First seen May 08, 2026 ยท Last updated May 08, 2026

Summary

This study allowed people with certain cancers (ovarian, basal cell, or colorectal) who had already shown benefit from the drug vismodegib in an earlier study to keep receiving it. The main goal was to track side effects and see how many people had to stop treatment due to them. Only 19 people took part, all from previous Genentech studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Hospital

    Oakland, California, 94609, United States

  • Comprehensive Cancer Care

    Palm Springs, California, 92262, United States

  • DermSurgery Associates, PA

    Houston, Texas, 77030, United States

  • Irfan Firdaus, D.O.

    Cincinnati, Ohio, 45242, United States

  • Johns Hopkins Univ Med Center

    Baltimore, Maryland, 21231, United States

  • Karmanos Cancer Institute..

    Detroit, Michigan, 48201, United States

  • Nevada Cancer Research Foundation

    Las Vegas, Nevada, 89169, United States

  • Stanford Univ Medical Center

    Stanford, California, 94305, United States

  • TGen Clinical Research Srvs

    Scottsdale, Arizona, 85258, United States

  • University Of Michigan

    Ann Arbor, Michigan, 48109-0934, United States

Conditions

Explore the condition pages connected to this study.